Colin Woodard, DO
Gastroenterology · Cranston, RINPI 1760820591
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,186 of the $10,207 with a category attached, or 90.0%. 29 manufacturers reported payments, led by AbbVie at 36.9% of the total.
Across 506 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Nestle Healthcare Nutrition Inc.$872
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$790
- Boston Scientific$744
- Johnson & Johnson$670
- Takeda Pharmaceuticals U.S.A., Inc.$629
- plus $3K from 23 others
What the payments were for
- Speaking & faculty fees$4004%
- Travel & lodging$6216%
- Food & beverage$9,18690%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 260 | $3,768 |
| Nestle Healthcare Nutrition Inc. | 42 | $872 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 39 | $790 |
| Boston Scientific | 6 | $744 |
| Johnson & Johnson(2 entities) | 29 | $670 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $629 |
| QOL Medical, LLC | 5 | $501 |
| Pfizer | 23 | $362 |
| Medtronic | 1 | $279 |
| Ardelyx, Inc. | 15 | $250 |
| Bristol Myers Squibb | 11 | $210 |
| Merck | 12 | $200 |
| Intercept Pharmaceuticals, Inc. | 8 | $169 |
| Regeneron Healthcare Solutions, Inc. | 3 | $142 |
| Madrigal Pharmaceuticals | 3 | $136 |
| Ipsen Biopharmaceuticals, Inc | 2 | $135 |
| Alnylam Pharmaceuticals Inc. | 2 | $51 |
| Sanofi | 2 | $50 |
| Phathom Pharmaceuticals, Inc. | 2 | $49 |
| UCB, Inc. | 2 | $33 |
| Braintree Laboratories, Inc. | 1 | $29 |
| Celltrion USA Inc. | 1 | $26 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Exact Sciences | 1 | $20 |
| Lilly USA, LLC | 1 | $17 |
| Capsovision, Inc. | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $12 |
| ERBE USA Inc | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,207 in reported general payments places this provider in the 80th percentile of 85 gastroenterology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 17 | $529,156 |
| RinvoqUpadacitinib | 14 | $104,661 |
| CreonLipase/Protease/Amylase | 38 | $86,199 |
| LinzessLinaclotide | 83 | $71,905 |
| ZenpepLipase/Protease/Amylase | 19 | $51,407 |
| Mesalamine | 52 | $27,085 |
| XifaxanRifaximin | 12 | $26,551 |
| IbsrelaTenapanor Hcl | 11 | $18,440 |
| ViberziEluxadoline | 11 | $17,556 |
| MotegrityPrucalopride Succinate | 15 | $16,533 |
| Dexlansoprazole DrDexlansoprazole | 43 | $12,263 |
| Omeprazole | 423 | $5,807 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 33 | $4,574 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,316 |
| Famotidine | 306 | $4,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $670 | $529,15617 claims |
| AbbVieRinvoq, Creon, Linzess, Viberzi | $3,768 | $280,321146 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $790 | $31,12545 claims |
| Ardelyx, Inc.Ibsrela | $250 | $18,44011 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $629 | $16,53315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 85 gastroenterology providers in Rhode Island.
Other gastroenterology in Cranston
- Robert BierwirthCranston$603K
- Morris ElevadoCranston$233K
- Thomas McGreenCranston$7K
- Robert WolfgangCranston$7K
- Paul RoderickCranston$5K
- Thomas SepeProvidence$307K
- Joseph LowneyWarwick$127K
- Paul AkermanProvidence$123K
- Sean FineProvidence$55K
- Breton RousselProvidence$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.